Funding Opportunity PAR-17-275 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose exploratory and confirmatory clinical trials focused on promising interventions, as well as biomarker-or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery. The program will utilize the cooperative agreement mechanism to enable milestone-drive projects.

Funding Opportunity PAR-17-277 from the NIH Guide for Grants and Contracts. This FOA encourages requests for access to research resources for multi-site exploratory and confirmatory clinical trials focused on promising interventions, as well as biomarker-or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery. Successful applicants will be given access to the NIH StrokeNet infrastructure. Following peer review, NINDS will prioritize trials among the highest scoring to be conducted in the NIH StrokeNet infrastructure. The NIH StrokeNet National Coordinating Center (NCC) will work with the successful applicant to implement the proposed study efficiently and the National Data Management Center (NDMC) will provide statistical and data management support. The NIH StrokeNet Regional Coordinating Centers (RCCs) and their affiliated clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol.

Funding Opportunity PAR-17-274 from the NIH Guide for Grants and Contracts. This FOA encourages applications for multi-site exploratory and confirmatory clinical trials focused on promising interventions, as well as biomarker-or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery. Successful applicants will collaborate and conduct the trial within the NIH StrokeNet. Following peer review, NINDS will prioritize trials among the highest scoring to be conducted in the NIH StrokeNet infrastructure. The NIH StrokeNet National Coordinating Center (NCC) will work with the successful applicant to implement the proposed study efficiently and the National Data Management Center (NDMC) will provide statistical and data management support. The NIH StrokeNet Regional Coordinating Centers (RCCs) and their affiliated clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol.

Notice NOT-CA-17-057 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-OD-17-009 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite research project applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.

Funding Opportunity RFA-OD-17-008 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite R03 applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.

Funding Opportunity RFA-OD-17-007 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite R01 applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.

Notice NOT-CA-17-062 from the NIH Guide for Grants and Contracts

Notice NOT-HS-17-016 from the NIH Guide for Grants and Contracts

Notice NOT-EY-17-006 from the NIH Guide for Grants and Contracts

Notice NOT-HL-17-512 from the NIH Guide for Grants and Contracts

Notice NOT-DA-17-035 from the NIH Guide for Grants and Contracts

Notice NOT-DA-17-034 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-17-273 from the NIH Guide for Grants and Contracts. To facilitate genomic research and the dissemination of its products, NHGRI supports genomic resources that are crucial for basic research, disease studies, model organism studies, and other biomedical research. Awards under this FOA will support the development and distribution of genomic resources that will be valuable for the broad research community, using cost-effective approaches. Such resources include (but are not limited to) databases and informatics resources (such as human and model organism databases, ontologies, and analysis toolsets), comprehensive identification and collections of genomic features (such as functional genomic elements), and standard data types produced using central sets of samples (such as structural variants in 1000 Genomes or GTEx samples). NCI is interested in any of the above types of resources that focus on cancer.

Notice NOT-MH-17-022 from the NIH Guide for Grants and Contracts

Notice NOT-MH-17-021 from the NIH Guide for Grants and Contracts

Notice NOT-OD-17-063 from the NIH Guide for Grants and Contracts

Notice NOT-GM-17-006 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-17-267 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support innovative research that will develop and apply computational tools and methods for modeling interactions between infectious agents and their hosts, disease spread, prediction systems and response strategies. The models should be useful to researchers, policymakers, or public health workers who want to better understand and respond to infectious diseases. This research opportunity encourages applications from institutions/organizations that propose to provide the scientific and public health communities better resources, knowledge, and tools to improve their ability to prepare for, identify, detect, control, and prevent the spread of infectious diseases caused by naturally occurring or intentionally released pathogens, including those relevant to biodefense.

Funding Opportunity PAR-17-272 from the NIH Guide for Grants and Contracts. NIMH seeks applications for research projects to evaluate the effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions affecting youth, adults, and older adults. This FOA encourages clinical trials to establish the effectiveness and test hypotheses regarding moderators, mediators, and mechanisms of action of post-acute phase therapeutic and services interventions that are matched to the stage of illness in terms of both their focus (e.g., consolidating and maintaining gains from initial treatment, managing residual symptoms/impairment, preventing relapse, promoting adherence and appropriate service use) and intensity/burden for promoting optimal longer-term outcomes.